Rare skin cancer patients face hidden mental health toll in advanced stages
A Swedish study of patients with mycosis fungoides and Sézary syndrome—rare cutaneous lymphomas—found that depression and quality-of-life impairment nearly doubled in advanced disease, driven largely by fatigue and itching. The findings suggest clinicians and healthcare systems should screen for psychological distress earlier, particularly as these incurable conditions progress.
Originaltitel: Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.
Kutana lymfom kräver bättre psykosocial uppföljning än dagens standard. En svensk studie från Sahlgrenska visar att 36 procent av patienter med avancerad mycosis fungoides eller Sézary syndrome utvecklar måttlig till svår depression, vilket är betydligt högre än de 16 procent som ses i tidig sjukdom. Klåda korrelerade starkt med försämrad livskvalitet (ρ=0,67), medan trötthet kopplade både till depression och ångest. Forskarna undersökte 60 patienter, varav 80 procent hade tidig sjukdomsstadium, och jämförde resultaten med psoriasis-kontroller. Fynden påpekar att regionvårdens dermatolognät bör implementera screeningprotokoll för depression och fatigue redan vid diagnos av avancerad sjukdom. Inköpschefer behöver säkra tillgång till både dermatologisk och psykiatrisk kompetens för denna patientgrupp. Resultaten öppnar möjlighet för supportiva interventioner och skapar underlag för framtida terapiutveckling riktad mot psykosocial belastning.
Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous lymphomas with limited data on psychological burden. This observational, cross sectional questionnaire study assessed symptom burden, psychological distress and quality of life (QoL) in patients with MF and SS in Western Sweden and compared outcomes with psoriasis. Sixty patients were included, 80% with early-stage disease. Most reported minimal depression, anxiety and QoL impairment. Moderate-to-severe depression occurred in 36% of advanced disease cases and 16% of early disease cases and moderate-to-severe QoL impairment in 33% and 17%, respectively. Pruritus correlated strongly with impaired QoL (ρ=0.67, p<0.001). Fatigue correlated with depression (Montgomery-Åsberg Depression Rating Scale Self-report (MADRS-S): ρ=0.60, Hospital Anxiety and Depression Scale-Depression subscale: ρ=0.63), anxiety (ρ=0.49) and QoL impairment (ρ=0.53), all p<0.001. Compared with psoriasis, patients reported lower pain and QoL impairment. Overall, psychological burden was limited but increased with advanced disease and fatigue severity.